BCB-214 / BrainChild Bio - LARVOL DELTA

Seattle-based BrainChild Bio…has closed a USD 116 million Series A financing to fund a pivotal registrational trial in diffuse intrinsic pontine glioma (DIPG)… (AllSci Corp) - "An undisclosed private family fund and foundation led the round, with participation from Seattle Children's...and WRF Capital, the investment arm of the Washington Research Foundation, as a new investor. Proceeds will primarily support the ILLUMINATE Phase II study (NCT07680439), a pivotal, single-arm registrational trial designed to support a future Biologics License Application (BLA) with the US FDA for BCB-276....Additional funds will advance BCB-214, a triple-targeting CAR T candidate directed at B7-H3, EGFR, and IL13Rα2 in glioblastoma, toward initial clinical testing."

Financing • Diffuse Intrinsic Pontine Glioma • Glioblastoma